Otsuka Pharmaceutical Europe Ltd.
Otsuka Pharmaceutical Europe was founded in 1998. Otsuka Pharmaceutical Europe markets drugs and health care products manufactured by its Japan-based parent, Otsuka Pharmaceutical. The company also conducts research and development of pharmaceuticals, focusing on the fields of gastroenterology, neurology, ophthalmology, and the cardiovascular system. Marketed drugs include schizophrenia treatment Abilify (through a partnership with Bristol-Myers Squibb), Adacolumn for inflammatory bowel disease, Mikelan for ocular glaucoma and hypertension, Pletal for peripheral vascular disease, and UBiT for gastrointestinal infection diagnosis.
Contact Details
Office Address
Otsuka Pharmaceutical Europe Ltd.
Hunton House, Highbridge Estate, Oxford Road
Uxbridge, Middlesex, UK UB81HU
Phone: +44-1895-207-100
Fax: +44-1895-207-115
Executives
Chairman
Tadasu Toba
Managing Director
Shinchi Kobayashi